Compare · ELTX vs NVO
ELTX vs NVO
Side-by-side comparison of Elicio Therapeutics Inc. (ELTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 3601.3x ELTX ($48.2M).
- NVO has been more active in the news (4 items in the past 4 weeks vs 2 for ELTX).
- NVO has more recent analyst coverage (25 ratings vs 4 for ELTX).
- Company
- Elicio Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $48.2M
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 4
- Recent ratings
- 4
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ELTX
- SEC Form DEF 14A filed by Elicio Therapeutics Inc.
- Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
- Elicio Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events
- SEC Form 4 filed by Director Adams Julian
- SEC Form 4 filed by Director Ashe Carol Gail
- SEC Form 4 filed by Director Chudnovsky Yekaterina
- SEC Form 4 filed by Director Nissenson Allen
- SEC Form 4 filed by Director Ruffolo Robert R
- SEC Form 4 filed by Director Wilson Karen J
- SEC Form 4 filed by Director Venkatesan Jay
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank